Abstract:The assessment and therapeutic significance of human epidermal growth factor receptor 2 (HER2) in breast cancer have historically been based on a standard binary system, that classifies patients according to their immunohistochemistry (IHC) and in situ hybridization (ISH) results: HER2-negative (IHC0, IHC1+, and IHC2+/ISH-); and HER2-positive (IHC2+/ISH+ and IHC3+). 1 The recent approval of Trastuzumab-Deruxtecan, a third-generation antibody-drug conjugate (ADC) for HER2-low (IHC1+ and IHC2+/ISH-) breast cancer patients has highlighted the need to adapt current HER2 assessment, to integrate the clinical needs of this new category of patients. 2,3 Updated guidelines for HER2-low assessment and reporting have now been issued by both the American Society of Clinical Oncology—College of American Pathologists (ASCO-CAP), and the European Society for Medical Oncology—Expert Consensus. These new guidelines affirm the previous ASCO-CAP 2018 HER2 scoring algorithm and maintain consistency in the nomenclature used to report HER2, according to the results of approved IHC and ISH assays. 2,3 The proper treatment course which derives from the interpretation of the HER2 IHC scoring result into HER2 over expressed, HER2 low, and HER2 not over expressed, is determined by the oncologist. 1,4 Current HER2 IHC testing is based on semiquantitative assays, that were developed to detect HER2 overexpression (IHC2+/ISH+, IHC3+). The interest in the lower end of the HER2 expression spectrum considering new ADC approvals raises questions on the capability of these assays to effectively classify patients across the range of HER2 expression, and more importantly to discriminate between HER2-negative (IHC0), HER2-low (IHC1+, IHC2+/ISH-), and HER2-positive (IHC2+/ISH+ and IHC3+/ISH+). 5,6 These questions are clinically relevant. Some patients classified in the IHC0 category following the ASCO/CAP guidelines for HER2 scoring, show a faint to weak incomplete membrane staining in <10% of tumor cells, which is equivalent to a score of <1+ and could fit in the new HER2-ultralow category. Recent data suggests that these patients could equally benefit from T-DXd therapy. 6 Although the potential mechanism of action of these new ADCs in HER2 IHC0 is not yet well understood, some studies demonstrate a quantitative relationship between the uptake amount of the cytotoxic payload found in ADCs and the level of expression of the targeted antigen. 7,8 In vitro studies have demonstrated that threshold densities for efficient binding and internalization of HER2-targeted ADCs are between 50,000 to 200,000 HER2 receptor molecules on the cell membrane. 7,9 However, given multiple reports of a potentially beneficial response from T-DXd in some patients with IHC scores between 0 and 1+ (0<ihc<1+), efficacy="" for="" her2="" is="" it="" likely="" lower. 6,10 From the perspective of a pathologist routinely performing HER2 scoring on breast cancer specimens, the fundamental question is how to accurately identify and differentiate "true" HER2-negative (IHC0) cases from "borderline" (0<ihc<1+) achieve="" efficacy. 10 The effectiveness of the HER2 assays available in the market to detect HER2 expression in the lower range is not the same, with multiple reports suggesting a higher sensitivity of some over others. 11,12 This variability arises from disparities in preanalytical procedures, antibody selection, staining conditions, and interpretation criteria, among other factors.</ihc </ihc

Performance of HER2 DAKO HercepTest and Ventana 4B5 Immunohistochemical Assays on Detecting HER2 Gene-Amplification in Uterine Serous Carcinomas

HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.

Comparision of HER2/neu Oncogene Detected by Chromogenic In-Situ Hybridization and Immunohistochemistry in Breast Cancer

HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).

A Comparative Study on HER-2 Expression by Immunohistochemistry and Fluorescence in Situ Hybridization in Breast Cancer Tissue

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients

[Assessment of HER2 Gene Amplification in Breast Cancer: a Comparison of Dual-Color In-Situ Hybridization and Fluorescence In-Situ Hybridization].

[Analysis of HER2 Gene Amplification and Its Protein Expression in 165 Cases of Breast Carcinoma: Comparison of Chromogenic In-Situ Hybridization and Immunohistochemistry].

Investigation of HER-2 status evaluated by both IHC and FISH approaches in 278 cases of invasive breast carcinoma

Comparing the Sensitivity of HER2 Epitope Detection of HercepTest mAb pharmDx (Dako Omnis, GE001) and Ventana PATHWAY Anti-HER-2/neu (4B5) Using IHC Calibrators

In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer

Determination of HER2 Gene Amplification by Chromogenic in Situ Hybridization (CISH) in Archival Breast Carcinoma.

Chromogenic in Situ Hybridization is a Reliable Method for DetectingHER2Gene Status in Breast Cancer

An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Outcomes and the International Endocervical Adenocarcinoma Criteria and Classification

Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization

Detection of HER-2 Mrna and Protein Expression in Breast Cancer Tissues by Using Chromogenic in Situ Hybridization and Immunohistochemistry Methods

Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer

Concordance between pathologists and between specimen types in detection of HER2-low breast carcinoma by immunohistochemistry

Concordance among the Three Commercially Available PD-L1 Assays for Esophageal Squamous Cell Carcinoma

Semi-automated analysis of HER2 immunohistochemistry in invasive breast carcinoma using whole slide images: utility for interpretation in clinical practice

Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study